Moderna said the $3B share repurchase program announced in February 2022 was completed early in the fourth quarter 2022. The company has commenced repurchases from the additional $3B program announced in August 2022, and currently has $2.8B remaining under this latest authorization.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MRNA:
- Moderna Earnings Update: Did it Beat Estimate Forecasts?
- Moderna Falls as Q4 Results Disappoint
- Moderna, Merck granted FDA Breakthrough Therapy Designation for mRNA-4157/V940
- Moderna, Life Edit enter collaboration for in vivo gene editing therapies
- Moderna says non-inferiority endpoint not met for B strains in flu vaccine study